Desktop Genetics is a technology company.
Desktop Genetics has raised $2.4M across 2 funding rounds.
Desktop Genetics has raised $2.4M in total across 2 funding rounds.
Desktop Genetics has raised $2.4M in total across 2 funding rounds.
Desktop Genetics's investors include Mogrify, Sana Capital, Boundary Capital Partners LLP.
Desktop Genetics is a UK-based biotechnology company founded in 2012 that develops AI-powered software platforms for genome editing, primarily using CRISPR technology to design, analyze, and optimize DNA constructs and experiments.[1][2][3][6] Its flagship products, including the DESKGEN AI platform and CRISPR Library tools, serve pharmaceutical companies, biotech firms, academic labs, and researchers worldwide by solving challenges in precise gene editing, off-target effect minimization, and data processing for drug discovery, functional genomics, cell therapy, and personalized medicine.[2][3][5][6] With tools used by over 1,800 organizations—including four of the top five pharmaceutical companies—the company has raised $3.15M, employs 10-100 staff, and generates around $5M in annual revenue, demonstrating steady growth in the bioinformatics space.[1][2][4][5]
Desktop Genetics was founded in 2012 by three University of Cambridge graduates aiming to help researchers discover and treat root genetic causes of human diseases by integrating genomics with data science.[3][6] Initially focused on DNA design, synthesis, assembly, and management via its AutoClone platform, the company pivoted in 2013 with the rise of CRISPR-Cas9, shifting to specialized bioinformatics for gene editing.[1][5][6] Key milestones include four years of R&D to build DESKGEN AI—trained on the world's largest empirical genome editing database—and acquisition by Celixir plc in June 2018, a cell and gene therapy firm founded by Nobel laureate Sir Martin Evans.[3] Early traction came from supporting thousands of labs globally, evolving into partnerships with top pharma and institutions like University College London.[2][3]
Desktop Genetics rides the CRISPR revolution and Moore's Law-like advances in genetic tech, where computational tools democratize genome assembly and editing—enabling laptop-based research that once required months and expensive labs.[1][6] Perfect timing aligns with exploding demand for precise gene therapies amid rising data volumes (e.g., terabytes per cell), fueled by market forces like personalized medicine, cell/gene therapy growth, and AI integration in biotech.[2][3][5][6] It influences the ecosystem by powering pharma drug discovery, academic breakthroughs, and clinical CRISPR applications, lowering barriers for global researchers and contributing to partnerships advancing therapies.[2][3]
Desktop Genetics is poised to expand DESKGEN's role in AI-optimized CRISPR workflows as gene editing scales toward routine clinical use, potentially integrating with emerging pangenomics and alternative nucleases for broader therapeutic delivery.[1][3][6] Trends like AI-driven bioinformatics, high-throughput NGS, and cell therapy demand will propel growth, especially post-2018 Celixir acquisition enhancing synergies in incurable disease treatments.[3] Its influence may evolve from design tools to full cognitive platforms revolutionizing personalized medicine, solidifying leadership as genetics converges with digital scalability.[6] This positions it as a key enabler in biotech's next wave, transforming complex gene research into accessible innovation.
Desktop Genetics has raised $2.4M across 2 funding rounds. Most recently, it raised $2.0M Venture Round in September 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2015 | $2.0M Venture Round | Mogrify, Sana Capital | |
| Aug 1, 2013 | $430K Seed | Boundary Capital Partners LLP, Mogrify, Sana Capital |